Chen Juan, Cheng Guo-Hua, Chen Li-Pai, Pang Ting-Yuan, Wang Xiao-Le
Department of Pharmacy, The Affiliated Cancer Hospital of Guangzhou Medical College, Guangzhou, China.
Asian Pac J Cancer Prev. 2013;14(5):3057-62. doi: 10.7314/apjcp.2013.14.5.3057.
Selecting chemotherapy regimens guided by chemosensitivity tests can provide individualized therapies for cancer patients. The 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H- tetrazolium, inner salt (MTS) assay is one in vitro assay which has become widely used to evaluate the sensitivity to anticancer agents. The aim of this study was to evaluate the clinical applicability and accuracy of MTS assay for predicting chemotherapeutic response in unresectable NSCLC patients.
Cancer cells were isolated from malignant pleural effusions of patients by density gradient centrifugation, and their sensitivity to eight chemotherapeutic agents was examined by MTS assay and compared with clinical response.
A total of 37 patients participated in this study, and MTS assay produced results successfully in 34 patients (91.9%). The sensitivity rates ranged from 8.8% to 88.2%. Twenty-four of 34 patients who received chemotherapy were evaluated for in vitro-in vivo response analysis. The correlation between in vitro chemosensitivity result and in vivo response was highly significant (P=0.003), and the total predictive accuracy, sensitivity, specificity, positive predictive value, and negative predictive value for MTS assay were 87.5%, 94.1%, 71.4%, 88.9%, and 83.3%, respectively. The in vitro sensitivity for CDDP also showed a significant correlation with in vivo response (P=0.018, r=0.522).
MTS assay is a preferable in vitro chemosensitivity assay that could be use to predict the response to chemotherapy and select the appropriate chemotherapy regimens for unresectable NSCLC patients, which could greatly improve therapeutic efficacy and reduce unnecessary adverse effects.
依据化疗敏感性试验来选择化疗方案可为癌症患者提供个体化治疗。3-(4,5-二甲基噻唑-2-基)-5-(3-羧甲氧基苯基)-2-(4-磺基苯基)-2H-四唑鎓内盐（MTS）检测是一种体外检测方法，已被广泛用于评估对抗癌药物的敏感性。本研究的目的是评估MTS检测在预测不可切除的非小细胞肺癌（NSCLC）患者化疗反应中的临床适用性和准确性。
通过密度梯度离心从患者的恶性胸腔积液中分离癌细胞，采用MTS检测法检测其对8种化疗药物的敏感性，并与临床反应进行比较。
共有37例患者参与本研究，34例患者（91.9%）成功获得MTS检测结果。敏感率在8.8%至88.2%之间。对34例接受化疗的患者中的24例进行了体外-体内反应分析。体外化疗敏感性结果与体内反应之间的相关性非常显著（P=0.003），MTS检测的总预测准确性、敏感性、特异性、阳性预测值和阴性预测值分别为87.5%、94.1%、71.4%、88.9%和83.3%。顺铂的体外敏感性与体内反应也显示出显著相关性（P=0.018，r=0.522）。
MTS检测是一种较好的体外化疗敏感性检测方法，可用于预测化疗反应并为不可切除的NSCLC患者选择合适的化疗方案，这可大大提高治疗效果并减少不必要的不良反应。
